期刊文献+

来氟米特与低剂量甲氨蝶呤联合塞来昔布致类风湿关节炎患者重度骨髓抑制伴肝肾功能损害 被引量:11

Severe bone marrow suppression and hepatorenal function lesion induced by leflunomide and low dose of methotrexate and celecoxib combination therapy
原文传递
导出
摘要 1例65岁类风湿关节炎男性患者在使用来氟米特(20 mg,po,qd)与甲氨蝶呤(10 mg,po,qw)联合塞来昔布(0.2 g,po,qd)治疗5周后出现口腔溃疡、咳嗽、咳血痰、高热和咽痛。入院后血常规示重度骨髓抑制,胸部CT示双肺炎症,转氨酶、血肌酐、尿素氮均较用药前明显升高。患者使用可疑药物治疗前血常规、肝功能正常,肾功能轻度异常,因此考虑来氟米特与甲氨蝶呤及塞来昔布联用致严重骨髓抑制伴肝、肾功能损害。予停用可疑药物及相关对症治疗,患者血细胞逐渐回升、肺部炎症得到控制,肝、肾功能逐步好转,病情趋于稳定。 A 65- year- old male patient with rheumatoid arthritis developed mouth ulcers, coughing, expectoration with blood, hyperpyrexia and pharyngalgia after receiving 5 weeks of leflunomide (20 mg, po, qd) and methotrexate (10 rag, po, qw) combined with celecoxib (0.2 g, po, qd) therapy. On hospitalization, routine blood test showed severe bone marrow suppression. Computed tomography of the chest showed inflammation in both lungs. Serum transaminase, creatinine and urea nitrogen went up obviously than before. In view of the patient's normal blood counts, normal liver function and mild abnormality of renal function before the treatment, so severe bone marrow suppression accompanying hepatorenal function lesion was considered due to leflunomide and low dose of methotrexate and celecoxib. After stopping the suspected agents and implementing symptomatic treatment, the patient's blood counts increased gradually, the inflammation in both lungs was controlled, and hepatorenal function was improved with stable condition.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2016年第5期377-380,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 来氟米特 甲氨蝶呤 塞来昔布 药物不良反应 严重骨髓抑制 肺部感染 leflunomide methotrexate celecoxib adverse drug reaction severe bone marrowsuppression pulmonary infection
  • 相关文献

参考文献13

  • 1KREMER JM. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis [J]. Semin Arthritis Rheum, 1999, 29(1): 14-26.
  • 2BIRD P, GRIFFITHS H, TYMMS K, et ol. The SMILE study-- safety of methotrexate in combination with leflunomide in rheuma- toid arthritis[J]. J Rheumatol, 2013, 40(3): 228-235.
  • 3高洁生,谢希,吴轰,李芬,田静.甲氨蝶呤和来氟米特联合治疗重症类风湿关节炎15月的临床疗效[J].中国新药与临床杂志,2006,25(10):766-769. 被引量:7
  • 4EMERY P, BREEDVELD FC, LEMMEL EM, et al. A compa- rison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis[J]. Rheumatology (Oxford), 2000, 39(6): 655-665.
  • 5FAMULARO G, GASBARRONE L, MINISOLA G. Probable celecoxib-induced hepatorenal syndrome[J]. Ann Pharmacother, 2012, 46(4): 610-611.
  • 6TABIBIAN JH, TABIBIAN N, KAUFMAN DM. Late- onset celecoxib-induced combined hepato-nephrotoxicity[J]. Br J Clin Pharmacol, 2008, 66(1): 150-151.
  • 7DANDA D, ILIYAS MM, CHANDY SJ, et ol. How safe is celecoxib for Asian-Indian patients with rheumatic diseases?[J] Int J Rheum Dis, 2013, 16(1) : 24-29.
  • 8WEINBLATI" ME, DIXON JA, FALCHUK KR. Serious liver disease in a patient receiving methotrexate and leflunomide[J]. Arthritis Rheum, 2000, 43 (11 ) : 2609-2611.
  • 9WEINBLATT ME, DIXON JA, FALCHUK KR. Leflunomide- associated pancytopenia with or without methotrexate[J]. Ann Pharmacother, 2004, 38(7-8): 1206-1211.
  • 10TOTH P, BERND R. Severe leukopenia in a rheumatoid arthritis patient treated with a methotrexate/leflunomide combination [J]. Rev Bras Reumatol, 2014, 5(2): 152-154.

二级参考文献13

  • 1OSIRI M, SHEA B, ROBINSON V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis [J]. J Rheumatol, 2003, 30 (6) : 1182-1190.
  • 2SHARP T, STRAND V, LEUNG H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis:results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis[J]. Arthritis Rheum,2000, 43 (3) : 495-505.
  • 3KREMER JM, GENOVESE MC, CANNON GW, et al.Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial[J]. Ann Intern Med, 2002, 137(9): 726-733.
  • 4BRUCE B, FRIES JF. The Stanford Health Assessment Questio.nnaire: Dimensions and practical applications[J]. Health Qual Life Outcomes, 2003, 1 (1) : 20.
  • 5van der HEIJDE D. How to read radiographs according to the Sharp/van der Heijde method[J]. J Rheumatol, 2000, 27 ( 1 ) :261-263.
  • 6FELSON DT, ANDERSON JJ, BOERS M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis[J]. Arthritis Rheum, 1995, 38 (6):727-735.
  • 7O'DELL JR, LEFF R, PAULSEN G, et ol. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine,methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year-randomized, double-blind,placebo-controlled trial[J]. Arthritis Rheum, 2002, 46 (5):1164-1170.
  • 8GRIGOR C, CAPELL H, STIRLING A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study) : a single-blind randomised controlled trial[J].Lancet, 2004, 364(9430): 263-269.
  • 9ALETAHA D, SMOLEN JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observation study[J]. J Rheumatol, 2002, 29(8): 1631-1638.
  • 10American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update[J]. Arthritis Rheum 2002, 46 (2):328-323.

共引文献6

同被引文献114

引证文献11

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部